PDA1
MCID: PTN014
MIFTS: 60

Patent Ductus Arteriosus 1 (PDA1)

Categories: Blood diseases, Cardiovascular diseases, Fetal diseases, Genetic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Patent Ductus Arteriosus 1

MalaCards integrated aliases for Patent Ductus Arteriosus 1:

Name: Patent Ductus Arteriosus 1 56 29
Patent Ductus Arteriosus 56 12 74 52 36 6 15 62 32
Patent Ductus Arteriosus, Susceptibility to 56 13
Ductus Arteriosus, Patent 12 43
Pda1 56 52
Pda 56 52
Patent Ductus Arteriosus - Persisting Type 71
Patent Ductus Arteriosus Familial 52
Patency of the Ductus Arteriosus 52
Ductus Arteriosus Patent 54
Patent Ductus Botalli 12

Characteristics:

OMIM:

56
Inheritance:
autosomal recessive


HPO:

31
patent ductus arteriosus 1:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:13832
OMIM 56 607411
OMIM Phenotypic Series 56 PS607411
KEGG 36 H01630
ICD9CM 34 747.0
MeSH 43 D004374
NCIt 49 C84492
SNOMED-CT 67 83330001
ICD10 32 Q25.0
MedGen 41 C4282128
SNOMED-CT via HPO 68 258211005
UMLS 71 C0013274 C3495549

Summaries for Patent Ductus Arteriosus 1

OMIM : 56 Persistent patency of the ductus arteriosus, or patent ductus arteriosus (PDA), is the second most common congenital heart disease, affecting approximately 1 in 1,600 to 5,000 live births in the U.S. (Mitchell et al., 1971). In fetal life, the ductus arteriosus, a muscular artery, shunts blood from the pulmonary artery to the aorta, bypassing the lungs. Its abrupt closure at birth establishes the mature circulatory pattern and represents a dramatic example of vascular remodeling. Failure of this normal process results in persistent PDA, which left untreated can result in pulmonary hypertension and heart failure. Closure of the ductus is a complex process. Aspects of this process are regulated by oxygen tension and a decrease in levels of hormones such as prostaglandin E2. PDA occurring in preterm infants often closes spontaneously or in response to inhibitors of prostaglandin biosynthesis (Ramsay et al., 1987). Term PDA typically has not been regarded as a genetic disorder, because it most often occurs sporadically. Nonetheless, term PDA recurs among 5% of sibs of PDA cases (Polani and Campbell, 1960; Lamy et al., 1957), suggesting a genetic component to disease pathogenesis that has typically been presumed to be multifactorial. That single genes can influence this trait has been demonstrated by a mouse model of PDA resulting from disruption of the prostaglandin E2 receptor (Nguyen et al., 1997) and by rare syndromic forms of PDA such as Char syndrome (169100), an autosomal dominant disorder caused by mutations in the transcription factor TFAP2B (601601) (Mani et al., 2002). (607411)

MalaCards based summary : Patent Ductus Arteriosus 1, also known as patent ductus arteriosus, is related to char syndrome and aneurysm. An important gene associated with Patent Ductus Arteriosus 1 is PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11), and among its related pathways/superpathways are Vascular smooth muscle contraction and Cardiac conduction. The drugs Beractant and Poractant alfa have been mentioned in the context of this disorder. Affiliated tissues include heart, lung and brain, and related phenotypes are patent ductus arteriosus and homeostasis/metabolism

KEGG : 36 Patent ductus arteriosus (PDA) is a common congenital heart defect with both inherited and acquired causes. The ductus arteriosus (DA) is a fetal specific vascular connection between the main pulmonary artery and the aorta. After birth, the DA normally closes within the first several days of life. If present after the age of 3 month, this condition is known as PDA. PDA can cause significant problems, especially in premature infants. It can be associated with an increased incidence of chronic lung disease, intraventricular hemorrhage, and necrotizing enterocolitis. Clinicians may choose to treat the PDA in an attempt to minimize the risk of these complications. Prostaglandin inhibition using indomethacin or ibuprofen is the standard strategy to close the DA. Surgical closure of the DA is an alternative option. Autosomal dominant forms of PDA caused by mutation in the TFAP2B and PRDM6 gene has been reported. PDA has been reported in a few subjects with thoracic aortic aneurysm and rare genetic variants in MYH11 and ACTA2.

PubMed Health : 62 About patent ductus arteriosus: Patent ductus arteriosus (PDA) is a heart problem that affects some babies soon after birth. In PDA, abnormal blood flow occurs between two of the major arteries connected to the heart. These arteries are the aorta and the pulmonary (PULL-mun-ary) artery. Before birth, these arteries are connected by a blood vessel called the ductus arteriosus. This blood vessel is a vital part of fetal blood circulation. Within minutes or up to a few days after birth, the ductus arteriosus closes. This change is normal in newborns. In some babies, however, the ductus arteriosus remains open (patent). The opening allows oxygen-rich blood from the aorta to mix with oxygen-poor blood from the pulmonary artery. This can strain the heart and increase blood pressure in the lung arteries.

Wikipedia : 74 Patent ductus arteriosus (PDA) is a medical condition in which the ductus arteriosus fails to close... more...

Related Diseases for Patent Ductus Arteriosus 1

Diseases in the Patent Ductus Arteriosus 1 family:

Patent Ductus Arteriosus 2 Patent Ductus Arteriosus 3

Diseases related to Patent Ductus Arteriosus 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 494)
# Related Disease Score Top Affiliating Genes
1 char syndrome 32.5 TFAP2B TFAP2A TBX5 TBX20 MYH11
2 aneurysm 32.2 MYH11 FBN1 ACTA2
3 aortic dissection 32.0 MYH11 FBN1 ACTA2
4 pulmonic stenosis 32.0 PTPN11 MYH11 GATA4
5 aortic aneurysm, familial thoracic 1 31.7 MYH11 FBN1 ACTA2
6 tetralogy of fallot 31.6 TFAP2B TBX5 TBX20 PTPN11 PRODH NPPB
7 heritable thoracic aortic disease 31.6 MYH11 FBN1 ACTA2
8 patent foramen ovale 31.6 TBX5 TBX20 PTPN11 NPPB NKX2-5 GATA4
9 pulmonary valve stenosis 31.6 TBX5 PTPN11 NKX2-5 GATA4 FBN1
10 total anomalous pulmonary venous return 1 31.6 TBX5 NKX2-5 GATA4
11 loeys-dietz syndrome 31.5 MYH11 FBN1 ACTA2
12 atrioventricular block 31.4 TBX5 NPPB NKX2-5 GATA4
13 aortic valve disease 1 31.4 TBX5 TBX20 NKX2-5 MYH11 GATA4 FBN1
14 atrioventricular septal defect 31.4 TBX5 TBX20 NKX2-5 GATA4
15 aortic disease 31.4 MYH11 FBN1 ACTA2
16 orthostatic intolerance 31.4 TBX20 MYH11 MIR379 FBN1 ACTA2
17 heart disease 31.3 TFAP2B TBX5 TBX20 PTPN11 PRODH NPPB
18 wolff-parkinson-white syndrome 31.3 TBX5 TBX20 NPPB NKX2-5
19 ventricular septal defect 31.3 TBX5 PRODH NPPB NKX2-5 GATA4
20 tricuspid atresia 31.2 TBX5 TBX20 PRODH NKX2-5 GATA4
21 holt-oram syndrome 31.2 TFAP2B TBX5 TBX20 NKX2-5 GATA4
22 heart septal defect 31.2 TBX5 TBX20 PTPN11 PRODH NKX2-5 GATA4
23 left ventricular noncompaction 31.2 TBX5 TBX20 NKX2-5 GATA4
24 noonan syndrome with multiple lentigines 31.1 TBX5 PTPN11 NKX2-5 GATA4
25 heart valve disease 31.1 NPPB NKX2-5 MIR379 FBN1
26 aortic valve disease 2 30.9 TBX5 NPPB NKX2-5 MIR379 GATA4 FBN1
27 pectus excavatum 30.8 PTPN11 FBN1
28 respiratory failure 30.7 TNFRSF13B NPPB INPP5E GATA4
29 dilated cardiomyopathy 30.6 TBX5 TBX20 PTPN11 NPPB NKX2-5 GATA4
30 aortic valve insufficiency 30.6 NPPB MYH11 FBN1 ACTA2
31 dextro-looped transposition of the great arteries 30.6 TBX5 NPPB NKX2-5 GATA4
32 mitral valve insufficiency 30.6 TBX5 NPPB FBN1
33 periventricular leukomalacia 30.6 NPPB CPVL AVPR2
34 atrial heart septal defect 30.6 TFAP2B TBX5 TBX20 PTPN11 PRODH NPPB
35 double outlet right ventricle 30.6 TBX5 TBX20 NKX2-5 GATA4
36 eisenmenger syndrome 30.5 NKX2-5 GATA4
37 hypoplastic left heart syndrome 30.5 TBX5 TBX20 NPPB NKX2-5 GATA4
38 cleft palate, isolated 30.5 TNFRSF13B TFAP2A TBX5 PRODH INPP5E
39 digeorge syndrome 30.4 TBX5 TBX20 PRODH NKX2-5 GATA4
40 marfan syndrome 30.3 MYH11 FBN1 ACTA2
41 intestinal pseudoobstruction with patent ductus arteriosus and natal teeth 12.8
42 patent ductus arteriosus and bicuspid aortic valve with hand anomalies 12.8
43 congenital patent ductus arteriosus aneurysm 12.6
44 pulmonary artery coming from patent ductus arteriosus 12.6
45 fontaine progeroid syndrome 12.3
46 aortic aneurysm, familial thoracic 4 12.2
47 subvalvular aortic stenosis 11.9
48 heterotaxy, visceral, 1, x-linked 11.7
49 microcephaly, facial dysmorphism, renal agenesis, and ambiguous genitalia syndrome 11.7
50 ramos arroyo clark syndrome 11.7

Graphical network of the top 20 diseases related to Patent Ductus Arteriosus 1:



Diseases related to Patent Ductus Arteriosus 1

Symptoms & Phenotypes for Patent Ductus Arteriosus 1

Human phenotypes related to Patent Ductus Arteriosus 1:

31
# Description HPO Frequency HPO Source Accession
1 patent ductus arteriosus 31 HP:0001643

Symptoms via clinical synopsis from OMIM:

56
Cardiovascular Vascular:
patent ductus arteriosus

Clinical features from OMIM:

607411

MGI Mouse Phenotypes related to Patent Ductus Arteriosus 1:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.21 AVPR2 CPVL FBN1 GATA4 INPP5E MYH11
2 cardiovascular system MP:0005385 10.2 ACTA2 FBN1 GATA4 MYH11 NKX2-5 PRDM6
3 growth/size/body region MP:0005378 10.18 AVPR2 FBN1 GATA4 INPP5E MYH11 NKX2-5
4 embryo MP:0005380 10.09 FBN1 GATA4 INPP5E NKX2-5 PRDM6 PTPN11
5 integument MP:0010771 10.06 AVPR2 CPVL FBN1 GATA4 MYH11 NKX2-5
6 mortality/aging MP:0010768 10 AVPR2 CPVL FBN1 GATA4 INPP5E MYH11
7 limbs/digits/tail MP:0005371 9.86 FBN1 GATA4 INPP5E PRODH PTPN11 TBX5
8 muscle MP:0005369 9.61 ACTA2 FBN1 GATA4 MYH11 NKX2-5 PTPN11
9 respiratory system MP:0005388 9.23 FBN1 GATA4 MYH11 NKX2-5 PRDM6 PTPN11

Drugs & Therapeutics for Patent Ductus Arteriosus 1

PubMed Health treatment related to Patent Ductus Arteriosus 1: 62

Patent ductus arteriosus (PDA) is treated with medicines, catheter -based procedures, and surgery . The goal of treatment is to close the PDA. Closure will help prevent complications and reverse the effects of increased blood volume. Small PDAs often close without treatment . For full-term infants, treatment is needed if the PDA is large or causing health problems. For premature infants, treatment is needed if the PDA is causing breathing problems or heart problems. Talk with your child's doctor about treatment options and how your family prefers to handle treatment decisions.

Drugs for Patent Ductus Arteriosus 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Beractant Approved Phase 4 108778-82-1
2 Poractant alfa Approved Phase 4 129069-19-8
3 Respiratory System Agents Phase 4
4 Pulmonary Surfactants Phase 4
5
tannic acid Approved Phase 3 1401-55-4
6
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
8
Fenoldopam Approved Phase 2, Phase 3 67227-57-0, 67227-56-9 3341
9
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
10
Acetaminophen Approved Phase 3 103-90-2 1983
11
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
12
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
13
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
14 Tocotrienol Investigational Phase 3 6829-55-6
15 lysine Phase 3
16 Analgesics, Opioid Phase 3
17 Anesthetics Phase 3
18 Narcotics Phase 3
19 Anesthetics, General Phase 3
20 Anesthetics, Intravenous Phase 3
21 Vasodilator Agents Phase 2, Phase 3
22 Dopamine agonists Phase 2, Phase 3
23 Antihypertensive Agents Phase 2, Phase 3
24 Trace Elements Phase 3
25 Vitamins Phase 3
26 Retinol palmitate Phase 3
27 retinol Phase 3
28 Nutrients Phase 3
29 Micronutrients Phase 3
30 Tocopherols Phase 3
31 Tocotrienols Phase 3
32 Calciferol Phase 3
33 Pharmaceutical Solutions Phase 2, Phase 3
34 Antipyretics Phase 3
35
Pentoxifylline Approved, Investigational Phase 2 6493-05-6 4740
36
Tadalafil Approved, Investigational Phase 2 171596-29-5 110635
37
Azithromycin Approved Phase 2 83905-01-5 447043 55185
38
Fludrocortisone Approved, Investigational Phase 2 127-31-1 31378
39
Erythromycin Approved, Investigational, Vet_approved Phase 2 114-07-8 12560 441411
40
Meclocycline Investigational Phase 2 2013-58-3 5480760
41 Antioxidants Phase 2
42 Platelet Aggregation Inhibitors Phase 2
43 Radiation-Protective Agents Phase 2
44 Antibodies Phase 1, Phase 2
45 Rho(D) Immune Globulin Phase 1, Phase 2
46 Immunoglobulins, Intravenous Phase 1, Phase 2
47 Immunologic Factors Phase 1, Phase 2
48 gamma-Globulins Phase 1, Phase 2
49 Immunoglobulins Phase 1, Phase 2
50 Phosphodiesterase 5 Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 172)
# Name Status NCT ID Phase Drugs
1 Comparison Between the Effect of Oral Paracetamol Versus Oral Ibuprofen in the Treatment of Patent Ductus Arteriosus in Preterm and Low Birth Weight Infants Unknown status NCT03265782 Phase 4 ibuprofen;paracetamol
2 Serum Level Measurement of Oral Paracetamol and Oral Ibuprofen Unknown status NCT01544972 Phase 4 Oral paracetamol;Oral ibuprofen
3 THE EFFECT OF SUSTAINED LUNG INFLATION MANEUVER APPLIED THROUGH NASAL PRONG ON EARLY AND LATE RESPIRATORY MORBIDITIES IN PRETERM INFANTS Unknown status NCT02887924 Phase 4
4 Oral Paracetamol Versus Oral Ibuprofen Treatment Completed NCT01536158 Phase 4 Oral paracetamol;Oral ibuprofen
5 Ibuprofen and Renal Function in Premature Infants Completed NCT00217191 Phase 4 Ibuprofen
6 Randomized Pilot Study Comparing Oral Ibuprofen With Intravenous Ibuprofen in Very Low Birth Weight Infants With Patent Ductus Arteriosus Completed NCT00642330 Phase 4 oral ibuprofen;intravenous ibuprofen
7 Multicentre Randomised Controlled Trial of Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on Continuous Positive Airways Pressure Active, not recruiting NCT02140580 Phase 4
8 Safety and Efficacy of an Optimized Ibuprofen Dosing Regimen Versus Standard Dosing for Pharmacologic Closure of Patent Ductus Arteriosus Terminated NCT00961753 Phase 4 optimized ibuprofen;Standard Ibuprofen
9 Phase 4 Study of Curosurf (Poractant) and Survanta (Beractant) Surfactant Treatment in Very Premature Infants With Respiratory Distress Syndrome. Terminated NCT00767039 Phase 4 Survanta (beractant);Curosurf (poractant)
10 A Randomised Controlled Trial Comparing Ibuprofen And Indomethacin For The Treatment Of The Patent Ductus Arteriosus In Very Premature Infants Withdrawn NCT00470743 Phase 4 Ibuprofen;Indomethacin
11 Nasal Intermittent Mandatory Ventilation Versus Continuous Positive Airway Pressure After Extubation of Very Low Birth Weight Infants of the NEOCOSUR Network. Unknown status NCT01778829 Phase 3
12 Adding Paracetamol to Ibuprofen for Treatment of Patent Ductus Arteriosus in Preterm Infants: A Pilot, Double Blind, Randomized, Placebo-control Trial Completed NCT02002741 Phase 2, Phase 3 Paracetamol;Placebo
13 Randomized, Double-Blind Study of Ibuprofen L-Lysine Intravenous Solution in Premature Infants for the Early Treatment of Patent Ductus Arteriosus Completed NCT00440804 Phase 3 ibuprofen l-lysine iv solution (NeoProfen (R) )
14 Impact of Early Targeted Ibuprofene Treatment of Patent Ductus Arteriosus (PDA) on Long Term Neurodevelopmental Outcome in Very Premature Infants (TRIOCAPI) Completed NCT01630278 Phase 3 Ibuprofen;Placebo
15 Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP) Completed NCT00009646 Phase 3 indomethacin;Indomethacin;Placebo
16 Comparison of Intravenous Ibuprofen vs. Continuous Indomethacin in the Treatment of Patent Ductus Arteriosus Completed NCT00485160 Phase 3 Continuous indomethacin;ibuprofen
17 Randomised Controlled Clinical Trial of Echocardiographically Guided Versus Standard Ibuprofen Treatment for Patent Ductus Arteriosus: a Pilot Study Completed NCT01593163 Phase 3 Ibuprofen EchoG;Standard ibuprofen treatment
18 Management of Patent Ductus in Premature Infants Completed NCT00000494 Phase 3 indomethacin
19 High-dose Ibuprofen for Patent Ductus Arteriosus in Extremely Preterm Infants: a Randomized Controlled Study Completed NCT01243996 Phase 2, Phase 3 Ibuprofen
20 Liberal Versus Restrictive Platelet Transfusion for Treatment of Hemodynamically Significant Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates- A Randomized Open Label, Controlled Trial Completed NCT03022253 Phase 3 Paracetamol;Ibuprofen
21 L-Thyroxine Supplementation for Preterm Newborns Less Than 32 Weeks of Gestation With Transient Hypothyroxinemia of Prematurity: a Prospective Randomized Double-blind Trial Completed NCT01306227 Phase 3 L-Thyroxine;water
22 Efficacy and Safety of Continuous Infusion of Fentanyl for Pain Control in Preterm Newborn on Mechanical Ventilation Completed NCT00571636 Phase 3 Fentanyl;5% glucose solution
23 Management of the Patent Ductus Arteriosus in Premature Infants Trial (PDA Trial) Recruiting NCT03456336 Phase 3
24 Paracetamol Versus Ibuprofen in Premature Infants With Hemodynamically Significant Patent Ductus Arteriosus: a Randomized Clinical Trial Recruiting NCT04037514 Phase 3 Paracetamol;Ibuprofen
25 Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants Recruiting NCT02620761 Phase 2, Phase 3 Fenoldopam;0.9%NS
26 Phase III Clinical Trial, Randomized, Multicentre, Double Blind to Evaluate Two Guidelines for the Administration of Ibuprofen in the Treatment of Persistent Ductus Arteriosus Eco-guided: Impact in the Intestinal Prognosis Recruiting NCT04282941 Phase 3 Ibuprofen in continuous (24 hours) iv infusion and EchoG;IV bolus Ibuprofen slow (15 minutes) and EchoG
27 Effects of Fat-soluble Vitamins Supplementation in Early Life on Common Complications and Neural Development in Very Low Birth Weight Infants Recruiting NCT03876704 Phase 3 High dose of fat-Soluble Vitamin;Conventional dose of fat-Soluble Vitamin
28 Alternative Acetaminophen Treatment of the Hemodynamivally Significant Patent Ductus Arteriosus in Preterm Neonates Who Are Not Candidates for Enteral Administration: A Pilot Study Not yet recruiting NCT03604796 Phase 2, Phase 3 Rectal Solution;Intravenous Infusion
29 Paracetamol Versus Ibuprofen for Patent Ductus Arteriosus Closure in Preterm Infants. A Prospective, Randomized, Controlled, Double Blind, Multicenter Clinical Trial. Suspended NCT02056223 Phase 2, Phase 3 Intravenous paracetamol;Intravenous ibuprofen
30 An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants- A Randomized Pilot Study Terminated NCT00750581 Phase 2, Phase 3 Indomethacin
31 Comparison of the Efficacy of IV Acetaminophen Versus IV Indomethacin in Treatment of Hemodynamically Significant PDA in VLBW Infants Terminated NCT03537144 Phase 3 Indomethacin;Acetaminophen
32 New Therapeutic Approaches to the Resistant Patent Ductus Arteriosus (PDA) in Low Birth Weight Neonates Unknown status NCT00616382 Phase 2 Indomethacin;Pentoxifylline
33 TIME TO RE-EVALUATE THE KINDER GENTLER APPROACH TO PATENT DUCTUS ARTERIOSUS (PDA) IN THE PRETERM NEONATE Unknown status NCT02819414 Phase 2 Paracetamol drops
34 Paracetamol in the Treatment of Patent Ductus Arteriosus in the Premature Neonate Unknown status NCT01291654 Phase 2 Paracetamol;NSAID;D5W
35 The Best Treatment Strategy: Surgical Versus Pharmacological, to Close the Ductus Arteriosus Persistent in Preterm Infants. A Randomized Controlled Trial Unknown status NCT02602054 Phase 2 Control group
36 Comparison of Oral and Intravenous Ibuprofen for Treatment of Patent Ductus Arteriosus in Extremely Premature Infants: A Randomized Controlled Trial Unknown status NCT01149564 Phase 1, Phase 2 iv ibuprofen;oral ibuprofen
37 Prevention of Chikungunya Infection in Neonates: Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins Unknown status NCT02230163 Phase 1, Phase 2
38 Efficacy and Safety of Paracetamol in Comparison to Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants: A Randomized, Open Label, Comparator-controlled, Prospective Study Completed NCT02422966 Phase 2 Paracetamol;Ibuprofen
39 Efficacy and Safety of No Treatment Compared With Oral Ibuprofen Treatment for Patent Ductus Arteriosus in Preterm Infants: a Randomized, Double-blind, Placebo-controlled, Non-inferiority Clinical Trial Completed NCT02128191 Phase 2 Oral ibuprofen;Normal saline
40 Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus in Preterm infants-a Multicenter Trial Completed NCT01958320 Phase 2 NSAID
41 Comparison of 2 Different Indomethacin Dosing Protocols to Treat Infants Delivered at <28 Weeks Gestation With a Persistent Patent Ductus Arteriosus Completed NCT00187447 Phase 2 indomethacin (two different dosing regimens)
42 The Preterm Infants' Paracetamol Study Completed NCT01938261 Phase 2 paracetamol;0.45 % saline solution
43 Clinical Efficacy of Phosphodiesterase-5 Inhibitor Tadalafil in Eisenmenger Syndrome - A Randomised, Placebo Controlled, Double Blind, Crossover Study Completed NCT01200732 Phase 2 Tadalafil, placebo
44 Single Center, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of Acetaminophen in Preterm Infants Used in Combination With Ibuprofen for Closure of the Ductus Arteriosus Recruiting NCT03701074 Phase 2 Ibuprofen and acetaminophen;Ibuprofen and placebo
45 Extremely Low Gestational Age Infants' Paracetamol Study: a Randomized Trial Recruiting NCT03641209 Phase 1, Phase 2 Paracetamol 10mg/mL infusion solution
46 A Phase IIb Randomized, Placebo-controlled, Double-blind Trial of Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants Active, not recruiting NCT01778634 Phase 2 Azithromycin;Placebo
47 Impact of the Administration of Fludrocortisone on Fluid and Electrolyte Balance in Very Premature Infants: Pilot Study Active, not recruiting NCT03001089 Phase 2 Oral Fludrocortisone (enteral);Placebo Oral Tablet
48 Monotherapy (Ibuprofen) vs. Combination Therapy (Ibuprofen and Acetaminophen) in the Management of Patent Ductus Arteriosus in Premature Infants: A Randomized Controlled Trial Not yet recruiting NCT04026464 Phase 2 Intravenous Ibuprofen;Intravenous Ibuprofen + Oral Acetaminophen
49 Pharmacokinetics and Pharmacodynamics of Indomethacin Used for PDA Treatment in Extremely Preterm Neonates <27 Weeks Gestational Age Not yet recruiting NCT04025177 Phase 2 Indomethacin Injection
50 The Efficacy of LISA Technology With Noninvasive Ventilation in the Treatment of Respiratory Distress Syndrome in Preterm Neonates Not yet recruiting NCT04126382 Phase 2

Search NIH Clinical Center for Patent Ductus Arteriosus 1

Cochrane evidence based reviews: ductus arteriosus, patent

Genetic Tests for Patent Ductus Arteriosus 1

Genetic tests related to Patent Ductus Arteriosus 1:

# Genetic test Affiliating Genes
1 Patent Ductus Arteriosus 1 29

Anatomical Context for Patent Ductus Arteriosus 1

MalaCards organs/tissues related to Patent Ductus Arteriosus 1:

40
Heart, Lung, Brain, Kidney, Smooth Muscle, Testes, Thyroid

Publications for Patent Ductus Arteriosus 1

Articles related to Patent Ductus Arteriosus 1:

(show top 50) (show all 8223)
# Title Authors PMID Year
1
Genetics of patent ductus arteriosus susceptibility and treatment. 61 56
22414880 2012
2
Finding genetic contributions to sporadic disease: a recessive locus at 12q24 commonly contributes to patent ductus arteriosus. 61 56
12409608 2002
3
Response of the patent ductus arteriosus to indomethacin treatment. 61 56
3812411 1987
4
The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth. 56
9363893 1997
5
Congenital heart disease in 56,109 births. Incidence and natural history. 56
5102136 1971
6
Factors in the causation of persistent ductus arteriosus. 56
13736684 1960
7
Genetic and non-genetic factors in the etiology of congenital heart disease: a study of 1188 cases. 56
13410899 1957
8
B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus. 54 61
18981033 2009
9
Longitudinal changes of brain-type natriuretic peptide in preterm neonates. 61 54
16740863 2006
10
Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. 61 54
16222347 2005
11
The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates. 61 54
16027692 2005
12
Intraventricular Hemorrhage and Patent Ductus Arteriosus Ligation Association with Infant Mortality. 61
32278974 2020
13
Device deformation and left pulmonary artery obstruction after transcatheter patent ductus arteriosus closure in preterm infants. 61
32143922 2020
14
Early neurobehavior at 30 weeks postmenstrual age is related to outcome at term equivalent age. 61
32470768 2020
15
Endovascular Management of a Short-neck Thoracic Aortic Aneurysm With Patent Ductus Arteriosus. 61
32304690 2020
16
Improved ventilation in premature babies after transcatheter versus surgical closure of patent ductus arteriosus. 61
32253052 2020
17
The effects of latency period in PPROM cases managed expectantly. 61
32089027 2020
18
Device Closure of Patent Ductus Arteriosus in Adults. 61
32173055 2020
19
Clinical Outcomes After Percutaneous Patent Ductus Arteriosus Closure in Adults. 61
32536374 2020
20
Comparison of transcatheter patent ductus arteriosus closure between children and adults. 61
32494943 2020
21
The Thromboelastographic Profile at Birth in Very Preterm Newborns with Patent Ductus Arteriosus. 61
32485708 2020
22
Anomalous origin of a single coronary artery from the pulmonary artery associated with patent ductus arteriosus. 61
32508300 2020
23
Patent ductus arteriosus and cerebral, cardiac, and gut hemodynamics in premature neonates. 61
32513596 2020
24
Transcatheter intervention for doublesteal syndrome from isolation of the subclavian artery associated with patent ductus arteriosus. 61
32478691 2020
25
Assessing Patent Ductus Arteriosus (PDA) Significance on Cardiac Output by Whole-Body Bio-impedance. 61
32524206 2020
26
Variations in patterns of care across neonatal units and their associations with outcomes in very preterm infants: the French EPIPAGE-2 cohort study. 61
32571857 2020
27
Cardiorespiratory Events in Infants Born Preterm during the Transitional Period. 61
32446489 2020
28
Less invasive surfactant administration versus endotracheal surfactant instillation followed by limited peak pressure ventilation in preterm infants with respiratory distress syndrome in China: study protocol for a randomized controlled trial. 61
32527290 2020
29
Survival, Morbidities, and Developmental Outcomes among Low Birth Weight Infants with Congenital Heart Defects. 61
32485756 2020
30
Primary repair of transposition of the great arteries with an interrupted aortic arch: a case report and literature review. 61
32527284 2020
31
Outcomes of aortic coarctation surgical repair in adolescents and adults. 61
32221581 2020
32
Serial Doppler velocimetry of mesenteric and portal flow in very-low-birth-weight preterm neonates with and without patent ductus arteriosus. 61
32556575 2020
33
Is high platelet distribution width in the first hours of life can predict hemodynamically significant patent ductus arteriosus in preterm newborns? 61
30318943 2020
34
Ventricular Septal Defect Pulmonary Atresia: Provisional Bifurcation Strategy for Confluence Stenosis During Patent Ductus Arteriosis Stenting. 61
32416064 2020
35
Lung Ultrasound Score Predicts the Extravascular Lung Water Content in Low-Birth-Weight Neonates with Patent Ductus Arteriosus. 61
32538377 2020
36
Effect of Nonintervention vs Oral Ibuprofen in Patent Ductus Arteriosus in Preterm Infants: A Randomized Clinical Trial. 61
32539121 2020
37
Surgical ligation of patent ductus arteriosus in preterm neonates weighing less than 1500g: a 9-year single center experience. 61
32552772 2020
38
Diagnosis and treatment of infective endocarditis in pregnancy: a case report. 61
32448305 2020
39
Circulating Forms of B-Type Natriuretic Peptide in Very Preterm Infants. 61
32445356 2020
40
Role of dopamine and selective dopamine receptor agonists on mouse ductus arteriosus tone and responsiveness. 61
31816622 2020
41
The effect of preterm birth, recurrent laryngeal nerve lesion, and postnatal maturation on hyoid and thyroid movements, and their coordination in infant feeding. 61
32307182 2020
42
Blood urea in preterm infants on routine parenteral nutrition: A multiple linear regression analysis. 61
32423698 2020
43
Intracranial Vessel Stenosis in a Young Patient with an MYH11 Mutation: A Case Report and Review of 2 Prior Cases. 61
32081817 2020
44
Outcome of extremely low birth weight (ELBW) infants from a birth cohort (2013-2018) in a tertiary care unit in North India. 61
32060359 2020
45
Biomarkers of Kidney Injury in Very-low-birth-weight Preterm Infants: Influence of Maternal and Neonatal Factors. 61
32354927 2020
46
Identification of multilevel right-to-left shunting in a dog using nuclear scintigraphy imaging. 61
32574980 2020
47
Biological basis of child health 3: development of the cardiovascular system and congenital heart defects. 61
32420704 2020
48
Endostatin and ST2 are predictors of pulmonary hypertension disease course in infants. 61
32366869 2020
49
Phenotypic spectrum and transcriptomic profile associated with germline variants in TRAF7. 61
32376980 2020
50
Cerebral Hemodynamics Are Not Affected by the Size of the Patent Ductus Arteriosus. 61
32434188 2020

Variations for Patent Ductus Arteriosus 1

ClinVar genetic disease variations for Patent Ductus Arteriosus 1:

6 (show all 11) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 46;XX;ins(5;6)(p13;p24p25)dnTranslocation Pathogenic 267851
2 46;XY;inv(6)(p22q13)dninversion Pathogenic 267941
3 PTPN11 NM_002834.5(PTPN11):c.184T>G (p.Tyr62Asp)SNV Pathogenic 13329 rs121918460 12:112888168-112888168 12:112450364-112450364
4 46;XX;ins(2;9)(q24.3;p22.1p24.3)dnTranslocation Pathogenic 268044
5 INPP5E NM_019892.6(INPP5E):c.1132C>T (p.Arg378Cys)SNV Pathogenic/Likely pathogenic 400 rs121918130 9:139327634-139327634 9:136433182-136433182
6 TNFRSF13B NM_012452.2(TNFRSF13B):c.310T>C (p.Cys104Arg)SNV risk factor 5302 rs34557412 17:16852187-16852187 17:16948873-16948873
7 HYDIN NM_001270974.2(HYDIN):c.10816G>T (p.Gly3606Ter)SNV Likely pathogenic 598961 rs1567744830 16:70908340-70908340 16:70874437-70874437
8 46;XX;inv(7)(q21.2q34)inversion Likely pathogenic 267968
9 46;XY;t(2;14)(p22;q24.3)dnTranslocation Likely pathogenic 268037
10 VANGL1 NM_138959.3(VANGL1):c.523C>T (p.Arg175Trp)SNV Conflicting interpretations of pathogenicity 167818 rs142594314 1:116206600-116206600 1:115663979-115663979
11 HYDIN NM_001270974.2(HYDIN):c.6631G>A (p.Asp2211Asn)SNV Uncertain significance 598962 rs748644598 16:70977753-70977753 16:70943850-70943850

Expression for Patent Ductus Arteriosus 1

Search GEO for disease gene expression data for Patent Ductus Arteriosus 1.

Pathways for Patent Ductus Arteriosus 1

Pathways related to Patent Ductus Arteriosus 1 according to KEGG:

36
# Name Kegg Source Accession
1 Vascular smooth muscle contraction hsa04270

GO Terms for Patent Ductus Arteriosus 1

Cellular components related to Patent Ductus Arteriosus 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear chromatin GO:0000790 9.1 TFAP2B TFAP2A TBX5 TBX20 NKX2-5 GATA4

Biological processes related to Patent Ductus Arteriosus 1 according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription, DNA-templated GO:0045892 9.95 TFAP2B TFAP2A TBX20 PRDM6 NKX2-5
2 negative regulation of transcription by RNA polymerase II GO:0000122 9.91 TFAP2B TFAP2A TBX5 TBX20 PRDM6 NKX2-5
3 heart development GO:0007507 9.78 TBX5 PTPN11 NKX2-5 FBN1
4 kidney development GO:0001822 9.75 TFAP2B TFAP2A FBN1
5 muscle contraction GO:0006936 9.73 TBX20 MYH11 ACTA2
6 positive regulation of transcription, DNA-templated GO:0045893 9.7 TFAP2B TFAP2A TBX5 TBX20 NKX2-5 GATA4
7 embryonic heart tube development GO:0035050 9.57 TBX20 NKX2-5
8 cardiac muscle tissue morphogenesis GO:0055008 9.54 TBX20 NKX2-5
9 heart looping GO:0001947 9.54 TBX20 NKX2-5 GATA4
10 positive regulation of urine volume GO:0035810 9.52 TFAP2B NPPB
11 cardiac right ventricle morphogenesis GO:0003215 9.51 TBX20 GATA4
12 endocardial cushion development GO:0003197 9.49 TBX5 GATA4
13 forelimb morphogenesis GO:0035136 9.46 TFAP2B TBX5
14 cardiac muscle cell differentiation GO:0055007 9.43 TBX5 NKX2-5 GATA4
15 cardiac ventricle morphogenesis GO:0003208 9.4 NKX2-5 GATA4
16 bundle of His development GO:0003166 9.32 TBX5 NKX2-5
17 positive regulation of cardioblast differentiation GO:0051891 9.13 TBX5 NKX2-5 GATA4
18 atrial septum morphogenesis GO:0060413 8.92 TBX5 TBX20 NKX2-5 GATA4

Molecular functions related to Patent Ductus Arteriosus 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.88 TFAP2B TFAP2A TBX5 TBX20 NKX2-5 GATA4
2 sequence-specific DNA binding GO:0043565 9.8 TFAP2B TFAP2A TBX5 PRDM6 NKX2-5 GATA4
3 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.73 TFAP2B TFAP2A TBX5 TBX20 NKX2-5 GATA4
4 DNA-binding transcription factor activity GO:0003700 9.7 TFAP2B TFAP2A TBX5 TBX20 PRDM6 NKX2-5
5 proximal promoter sequence-specific DNA binding GO:0000987 9.54 TFAP2B TFAP2A GATA4
6 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.43 TFAP2B TFAP2A TBX5 TBX20 NKX2-5 GATA4
7 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.1 TFAP2B TFAP2A TBX5 TBX20 PRDM6 GATA4

Sources for Patent Ductus Arteriosus 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....